AI tool for detecting thyrotoxic states
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests an artificial intelligence tool designed to help detect overactive thyroid conditions (thyrotoxicosis). It may be an option for people with Graves' disease, whether newly diagnosed or currently in treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 22 years old or older.
- You have Graves' disease, either newly diagnosed or currently being treated.
- You are able to use the study software after it's explained to you.
- You agree to participate and sign a consent form.
- You do not have serious heart problems like arrhythmia or heart failure.
- You are not taking medications that strongly affect heart rate (except for short-acting beta-blockers used as needed).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study without birth control.
- You do not have other major health issues, severe psychiatric disorders, or substance use problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a wearable device called Glandy HYPER that helps doctors adjust your antithyroid medication dose for Graves' disease. It may offer a more precise and convenient way to manage your treatment.
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This study observes people with various thyroid conditions, including overactive or underactive thyroid, to learn more about how these disorders develop and progress over time. It may help improve future diagnosis and treatment.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.